Table 4.

Prostate cancer risk among statin users by quartiles of total cumulative quantity of medication usage

Prostate cancer riskNo. discordant pairs*Crude OR (95% CI)Adjusted OR (95% CI)
Overall
All statin users2,253/2,0671.09 (1.02-1.15)1.07 (1.00-1.16)
    14-167 DDD576/5331.08 (0.96-1.22)1.06 (0.94-1.19)
    168-446 DDD559/5271.06 (0.97-1.15)1.04 (0.95-1.13)
    447-914 DDD558/5261.06 (0.95-1.20)1.05 (0.93-1.18)
    915-6,781 DDD560/4831.16 (1.03-1.31)1.13 (1.00-1.28)
Advanced
All statin users196/2720.72 (0.60-0.87)0.75 (0.62-0.91)
    14-167 DDD66/730.91 (0.65-1.27)0.94 (0.67-1.31)
    168-446 DDD46/710.65 (0.45-0.94)0.68 (0.47-0.99)
    447-914 DDD44/710.62 (0.43-0.90)0.64 (0.44-0.94)
    915-6,781 DDD40/560.71 (0.48-1.07)0.74 (0.49-1.11)
Ptrend < 0.001Ptrend = 0.001
  • NOTE: Study population of all newly diagnosed prostate cancer cases in Finland in 1995 to 2002 and their individually matched controls.

  • * As conditional logistic regression is the analysis method, number of case-control pairs discordant to statin use is reported. Case: user-control: nonuser/Case: nonuser-control: user.

  • Adjusted for age, usage of diuretics, calcium-channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, metformin, sulfonylureas, and human insulin.

  • Cumulative quantity of statins purchased during the observed time period.